If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.50    0.025 (5.26%)
Bid:
0.45
Ask:
0.55
Spread: 0.10 (22.222%)
Market Cap: £4.66m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Contract win with US Group Purchasing Organisation

18 Jan 2010 07:00

RNS Number : 6741F
Surgical Innovations Group PLC
18 January 2010
 



Press Release 

18 January 2010

Surgical Innovations Group plc

("SI" or "the Group")

Contract win with leading US Group Purchasing Organisation

for laparoscopic instrumentation

Surgical Innovations Group plc (AIMSUN), the designer and manufacturer of innovative medical devices, is pleased to announce that its US Master Distributor, Surgical Innovations US Inc. ("SI USA"), has signed a three year agreement with one of the largest Group Purchasing Organisations ("GPO") in the US, effective from February 2010.

GPOs help hospitals reduce costs by aggregating volume to negotiate favourable purchasing terms with vendors. The agreement provides an opportunity for SI, through SI USA, to gain access to the GPO's 2,200 member hospitals in the US with its Resposable® laparoscopic instrumentation portfolio, Logi®Range, an ergonomic system which combines reusable handles with disposable scissor blades and graspers This provides surgeons with high quality, but cost effective instruments, for performing laparoscopic surgery. 

Commenting on the agreement, Graham Bowland, Managing Director of Surgical Innovations Limited, said: "This agreement with one of the US's leading GPOs strengthens SI's strategy of developing the Logi®Range brand through our collaboration with SI USA.  The 2,200 member hospitals represent a considerable proportion of all US hospitals, therefore the agreement provides us with significant access to the US laparoscopic instrumentation market, which is estimated to be worth $150 million per annum.  We look forward to seeing substantial sales growth of the Logi®Range as member hospitals are introduced to the brand."

Ends -

  For further information:

Surgical Innovations Group plc

Doug Liversidge, Chairman

Tel: +44 (0) 113 230 7597

www.surginno.com 

Graham Bowland, Finance Director

Tel: +44 (0) 113 230 7597

graham.bowland@surginno.co.uk 

www.surginno.com 

Westhouse Securities Limited

Tim Feather / Matthew Johnson

Tel: +44 (0) 113 246 2611

tim.feather@westhousesecurities.com

www.westhousesecurities.com 

Media enquiries:

Abchurch Communications

Sarah Hollins / Simone Elviss

Tel: +44 (0) 20 7398 7728

simone.elviss@abchurch-group.com

www.abchurch-group.com 

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery and industrial markets. The Group has two trading subsidiaries Surgical Innovations Limited and Haemocell Limited

The Group employs over 80 people and has its manufacturing facility based in Leeds, covering 32,000 square feet, which enables the in-house design and manufacture of its own products to the highest quality standards. Surgical Innovations, through an established network of 40 distribution partners, sells in all of the major medical markets including North America, Europe, South Africa, the Middle East, South-East Asia and Australia

Surgical Innovations Limited, which is the main division of the Group, is focused on developing medical instruments for the laparoscopic surgery market, minimally invasive surgery of the abdomen. The Group has pioneered the resposable™ concept, which combines both single use and reusable components which ensures an ongoing revenue stream and delivers the optimum procedure performance to cost ratio. The Groups products include:

YelloPort plus

a resposable™ laparoscopic port access system that combines both single-use and reusable components

Logi®Range

laparoscopic instrument system using Resposable® technology to deliver the cost effectiveness of a reusable instrument with the optimum performance of a disposable.

Quick Range

single-use instruments, with an ergonomic handle to ensure accurate control of the instrument. The range includes scissors, graspers and dissectors 

In addition to its own branded instruments, the Group also designs and manufactures devices on a private label basis for large medical device companies including Teleflex Medical, Gyrus, Olympus and Cardinal Health

Haemocell Limited specialises in equipment for Autologous Blood Transfusion, which is the collection and re-infusion of a patient's own blood either during or after surgery, eliminating the widely-documented risks of infection from donated blood

For more information, see www.surginno.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBAMRTMBTBBBM
Date   Source Headline
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSNotice of Interim Results
27th Jun 20223:15 pmRNSResult of AGM
27th Jun 20227:00 amRNSAGM Trading Statement
25th May 20227:00 amRNSPosting of 2021 Annual Report & Accounts
9th May 202212:41 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSFinal Results
21st Mar 20227:00 amRNSProduct launch in partnership with CMR Surgical
10th Mar 20227:00 amRNSNotice of Annual Results
17th Jan 20227:00 amRNSYear-end Trading Update
15th Nov 20217:00 amRNSChanges to Board Structure & CFO Appointment
10th Nov 20215:43 pmRNSGrant of Options
15th Sep 20217:00 amRNSHalf-year Report
27th Aug 20217:00 amRNSNotice of Interim Results
9th Jul 20212:29 pmRNSDirector/PDMR Shareholding
22nd Jun 20215:26 pmRNSResult of AGM
22nd Jun 20217:00 amRNSAGM Trading Statement
21st Jun 20217:00 amRNSWithdrawal of AGM Resolution
21st May 20217:00 amRNSPosting of Annual Report& Accounts & Notice of AGM
25th Mar 20217:00 amRNSFinal Results
22nd Mar 20217:00 amRNS3-year Exclusive UK distribution agreement
8th Mar 20217:00 amRNSNotice of annual results
15th Feb 20217:00 amRNS5-year USA distribution agreement
9th Feb 20217:00 amRNSLaunch of the Green Surgery Challenge
8th Jan 20217:00 amRNSDistalmotion’s Dexter Robot receives CE Mark
7th Jan 20217:00 amRNSFuture board change
21st Dec 20207:00 amRNSTrading update
17th Dec 20207:00 amRNSUS distribution agreement signed with Adler
7th Dec 20203:00 pmRNSReplacement of Auditor
2nd Dec 20207:00 amRNSProduct launch for Cellis Breast
25th Nov 20207:00 amRNSCentre for Sustainable Healthcare collaboration
25th Sep 202011:50 amRNSHolding(s) in Company
23rd Sep 20205:20 pmRNSHolding(s) in Company
21st Sep 20201:46 pmRNSHolding(s) in Company
18th Sep 20204:08 pmRNSResult of AGM
17th Sep 202012:54 pmRNSResult of Fundraise
17th Sep 20207:01 amRNSProposed Fundraise
8th Sep 20207:00 amRNSHalf-year Report
21st Aug 20207:00 amRNSNotice of results and Change of AGM 2020 Date
10th Aug 20205:57 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSPostponement of the Annual General Meeting 2020
4th Jun 20204:50 pmRNSDirector/PDMR Shareholding
4th Jun 20207:00 amRNSNHS Sustainability Webinar
28th May 20207:00 amRNSUpdate on trading &extension to banking facilities
31st Mar 20207:00 amRNSFinal Results
27th Mar 20203:05 pmRNSNotice of results and trading update
13th Jan 20207:00 amRNSYear-end Trading Update
11th Nov 20196:09 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSDirector/PDMR Shareholding
5th Nov 20192:56 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.